ACR

0.00%

6.7¢ acrux limited

Ann: Acrux presents at BioTrinity-ACR.AX, page-15

First 15 Last

Share
Profile

Follow
Slogger

7,518 Posts.

685

17/05/16

07:58

Post #: 17784583
Share

Originally posted by mwilson25 ↑

Thanks for these contributions. I am hoping to get a slightly higher price for my remaining shares so I guess positive recommendations are good.

I have no way to verify where we stand with the FDA, but certainly the court cases are in my view no reason to curtail marketing efforts. Given we have a strong case that all is well, then market away. Ditto with the FDA unless some behind the scenes gentleman's agreement has been struck in which Lilly agrees to keep marketing low key to avoid a warning on the bottle. I suppose the latter is possible. Anyway you bring an interesting perspective on this, that was not in my mind.

The Wilson stuff is likely just management PR. I have one company in my portfolio which told their analyst a whole lot of rot that led to a buy recommendation (not spec buy but buy) and a glowing analyst report, only to find just 8 weeks later that they are on the verge of going into administration and are in talks with suppliers to stitch up a deal to keep them afloat!!!!! Sp down 60% since the buy reco. The analysts know that if they keep in good with management then they get chosen for doing CRs and other work where they charge fat fees. Got to be careful unless we see some real measurable facts about progress. The absence of such facts and evidence of proper planning and scheduling is one of my main beefs with ACR management. I am not buying Wilson's view myself

Expand

totally agree - Wilson stuff is just PR - the Bio presentation should have had "similar" output by management but a lot of good that did to the SP. and target now only $0.70 - wasn't it $1 not too long ago by another firm??. I don't take any notice of these target prices by brokers - all self interest IMO. and as for FDA - yes Mitta very interesting take.

ACR Price at posting: 66.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Is oil undervalued?

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

WGX

Westgold sets its sights on top five producer status through merger with Karora

GRX

GreenX picks up prospective copper project in Germany

There are more pages in this discussion • 34 more messages in this thread...

First 15 Last

Add ACR (ASX) to my watchlist

(20min delay)
Last 6.7¢		Change 0.000(0.00%)		Mkt cap ! $19.47M

Open	High	Low	Value	Volume
6.7¢	6.7¢	6.5¢	$2.075K	31.02K

Buyers (Bids)

No.	Vol.	Price($)
2	480468	6.5¢

Sellers (Offers)

Price($)	Vol.	No.
6.7¢	41204	3

View Market Depth

No.	Vol.	Price($)
2	480468	0.065
1	71240	0.064
1	20918	0.063
1	60640	0.062
1	10000	0.061

Price($)	Vol.	No.
0.067	41204	3
0.070	107594	3
0.072	30000	1
0.075	15000	1
0.079	50000	1

Last trade - 14.15pm 02/08/2024 (20 minute delay)

ACR (ASX) Chart

Ann: Acrux presents at BioTrinity-ACR.AX, page-15

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

GreenX picks up prospective copper project in Germany

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Acrux presents at BioTrinity-ACR.AX, page-15

Top Stories

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

GreenX picks up prospective copper project in Germany

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News